Current management of colorectal liver metastases

References

• Ferlay J , ShinHR, BrayF, FormanD, MathersC, ParkinDM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer127(12), 2893–2917 (2010).
   PubMed Web of Science ®Google Scholar
• Stangl R , Altendorf-HofmannA, CharnleyRM, ScheeleJ. Factors influencing the natural history of colorectal liver metastases. Lancet343(8910), 1405–1410 (1994).
   PubMed Web of Science ®Google Scholar
• Weiss L , GrundmannE, TorhorstJet al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol.150(3), 195–203 (1986).
   PubMed Web of Science ®Google Scholar
• Felekouras ES , KaparelosDC, PapalambrosE. The history of liver surgery, hepatectomy and haemostasis. Hell. J. Surg.82(5), 280–296 (2010).
   Google Scholar
• Bouchahda M , LéviF, AdamR, RougierP. Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. Eur. J. Cancer47(18), 2681–2690 (2011).
   PubMed Web of Science ®Google Scholar
• Logan RF , PatnickJ, NickersonCet al. Outcomes of the bowel cancer screening programme (BCSP) in england after the first 1 million tests. Gut61(10), 1439–1446 (2012).
   PubMed Web of Science ®Google Scholar
• Anaya DA , BeckerNS, AbrahamNS. Global graying, colorectal cancer and liver metastasis: new implications for surgical management. Crit. Rev. Oncol. Hematol.77(2), 100–108 (2011).
   PubMed Web of Science ®Google Scholar
• Merkel S , BialeckiD, MeyerT, MüllerV, PapadopoulosT, HohenbergerW. Comparison of clinical risk scores predicting prognosis after resection of colorectal liver metastases. J. Surg. Oncol.100(5), 349–357 (2009).
   PubMed Web of Science ®Google Scholar
• Chang GJ , SkibberJM, FeigBW, Rodriguez-BigasM. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann. Surg.246(2), 215–221 (2007).
   PubMed Web of Science ®Google Scholar
• Haggar FA , BousheyRP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin. Colon Rectal Surg.22(4), 191–197 (2009).
   PubMedGoogle Scholar
• Poston GJ , FiguerasJ, GiulianteFet al. Urgent need for a new staging system in advanced colorectal cancer. J. Clin. Oncol.26(29), 4828–4833 (2008).
   PubMed Web of Science ®Google Scholar
• Lazorthes F , NavarroF, YchouM, DelperoJR, RougierP. Therapeutic management of hepatic metastases from colorectal cancers. Gastroenterol. Clin. Biol.27, B7 (2003).
   PubMedGoogle Scholar
• Van Cutsem E , NordlingerB, AdamRet al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur. J. Cancer42(14), 2212–2221 (2006).
   PubMed Web of Science ®Google Scholar
• Fong Y , FortnerJ, SunRL, BrennanMF, BlumgartLH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg.230(3), 309–318; discussion 318–321 (1999).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , GuiguetM, VaillantJCet al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association française de chirurgie. Cancer77(7), 1254–1262 (1996).
   PubMed Web of Science ®Google Scholar
• Rees M , TekkisPP, WelshFK, O’RourkeT, JohnTG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann. Surg.247(1), 125–135 (2008).
   PubMed Web of Science ®Google Scholar
• Zakaria S , DonohueJH, QueFGet al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann. Surg. 246(2), 183–191 (2007).
   PubMed Web of Science ®Google Scholar
• Gomez D , CameronIC. Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise?HPB (Oxford)12(4), 227–238 (2010).
   PubMed Web of Science ®Google Scholar
• Poston GJ , TaitD, O’ConnellS, BennettA, BerendseS; Guideline Development Group. Diagnosis and management of colorectal cancer: summary of NICE guidance. BMJ343, d6751 (2011).
   PubMedGoogle Scholar
• Saini S . Imaging of the hepatobiliary tract. N. Engl. J. Med.336(26), 1889–1997 (1894).
   Google Scholar
• Garden OJ . Hepatobiliary and Pancreatic Surgery (5th Edition).Elsevier Saunders, Edinburgh, UK (2013).
   Google Scholar
• Huppertz A , BalzerT, BlakeboroughAet al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology230(1), 266–275 (2004).
   PubMed Web of Science ®Google Scholar
• Xu LH , CaiSJ, CaiGX, PengWJ. Imaging diagnosis of colorectal liver metastases. World J. Gastroenterol.17(42), 4654–4659 (2011).
   PubMed Web of Science ®Google Scholar
• Scurr ED , CollinsDJ, TempleL, KaranjiaN, LeachMO, KohDM. Appearances of colorectal hepatic metastases at diffusion-weighted MRI compared with histopathology: initial observations. Br. J. Radiol.85(1011), 225–230 (2012).
   PubMed Web of Science ®Google Scholar
• Koh DM , BrownG, RiddellAMet al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur. Radiol.18(5), 903–910 (2008).
   PubMed Web of Science ®Google Scholar
• Wiering B , VogelWV, RuersTJ, OyenWJ. Controversies in the management of colorectal liver metastases: role of PET and PET/CT. Dig. Surg. 25(6), 413–420 (2008).
   PubMed Web of Science ®Google Scholar
• Kochhar R , LiongS, ManoharanP. The role of FDG PET/CT in patients with colorectal cancer metastases. Cancer Biomark.7(4), 235–248.2010.
   PubMed Web of Science ®Google Scholar
• Berger KL , NicholsonSA, DehdashtiF, SiegelBA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am. J. Roentgenol.174(4), 1005–1008 (2000).
   PubMed Web of Science ®Google Scholar
• D’Angelica M , FongY, WeberSet al. The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann. Surg. Oncol.10(2), 183–189 (2003).
   PubMed Web of Science ®Google Scholar
• Dunne DF , GaughranJ, JonesRPet al. Routine staging laparoscopy has no place in the management of colorectal liver metastases. Eur. J. Surg. Oncol.39(7), 721–725 (2013).
   PubMed Web of Science ®Google Scholar
• Snowden CP , PrentisJ, JacquesBet al. Cardiorespiratory fitness predicts mortality and hospital length of stay after major elective surgery in older people. Ann. Surg.257(6), 999–1004 (2013).
   PubMed Web of Science ®Google Scholar
• Grünhagen D , JonesRP, TreasureT, VasilakisC, PostonGJ. The history of adoption of hepatic resection for metastatic colorectal cancer: 1984–1995. Crit. Rev. Oncol. Hematol.86(3), 222–231 (2013).
   PubMed Web of Science ®Google Scholar
• Minagawa M , MakuuchiM, TorzilliGet al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann. Surg.231(4), 487 (2000).
   PubMed Web of Science ®Google Scholar
• Abdalla EK , AdamR, BilchikAJ, JaeckD, VautheyJN, MahviD. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol.13(10), 1271–1280 (2006).
   PubMed Web of Science ®Google Scholar
• Malde DJ , KhanA, PrasadKR, ToogoodGJ, LodgeJP. Inferior vena cava resection with hepatectomy: challenging but justified. HPB (Oxford)13(11), 802–810 (2011).
   PubMed Web of Science ®Google Scholar
• Shindoh J , TzengCW, AloiaTAet al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann. Surg. Oncol.20(8), 2493–2500 (2013).
   PubMed Web of Science ®Google Scholar
• Zimmitti G , RosesRE, AndreouAet al. Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: an experience with 2,628 consecutive resections. J. Gastrointest. Surg.17(1), 57–65 (2013).
   PubMed Web of Science ®Google Scholar
• Guglielmi A , RuzzenenteA, ConciS, ValdegamberiA, IaconoC. How much remnant is enough in liver resection?Dig. Surg.29(1), 6–17 (2012).
   PubMed Web of Science ®Google Scholar
• Roberts KJ , BharathyKG, LodgeJP. Kinetics of liver function tests after a hepatectomy for colorectal liver metastases predict post-operative liver failure as defined by the international study group for liver surgery. HPB (Oxford)15(5), 345–351 (2013).
   PubMed Web of Science ®Google Scholar
• Hanje AJ , PatelT. Preoperative evaluation of patients with liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol.4(5), 266–276 (2007).
   PubMedGoogle Scholar
• Yin Z , LiuC, ChenYet al. Timing of hepatectomy in resectable synchronous colorectal liver metastases (SCRLM): simultaneous or delayed? Hepatology57(6), 2346–2357 (2013).
   PubMed Web of Science ®Google Scholar
• Mayo SC , PulitanoC, MarquesHet al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J. Am. Coll. Surg.216(4), 707–716; discussion 716–718 (2013).
   PubMed Web of Science ®Google Scholar
• de Rosa A , GomezD, HossainiSet al. Stage IV colorectal cancer: outcomes following the liver-first approach. J. Surg. Oncol.108(7), 444–449 (2013).
   PubMed Web of Science ®Google Scholar
• Kooby DA , StockmanJ, Ben-PoratLet al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann. Surg.237(6), 860–869; discussion 869–870 (2003).
   PubMed Web of Science ®Google Scholar
• Lesurtel M , SelznerM, PetrowskyH, McCormackL, ClavienPA. How should transection of the liver be performed?: a prospective randomized study in 100 consecutive patients: comparing four different transection strategies. Ann. Surg.242(6), 814–822; discussion 822–823 (2005).
   PubMed Web of Science ®Google Scholar
• Gurusamy KS , PamechaV, SharmaD, DavidsonBR. Techniques for liver parenchymal transection in liver resection. Cochrane Database Syst. Rev.1, CD006880 (2009).
   Google Scholar
• van Dam RM , Wong-Lun-HingEM, van BreukelenGJet al. Open versus laparoscopic left lateral hepatic sectionectomy within an enhanced recovery ERAS® programme (ORANGE II-trial): study protocol for a randomised controlled trial. Trials13, 54 (2012).
   PubMedGoogle Scholar
• Nguyen KT , LaurentA, DagherIet al. Minimally invasive liver resection for metastatic colorectal cancer: a multi-institutional, international report of safety, feasibility, and early outcomes. Ann. Surg.250(5), 842–848 (2009).
   PubMed Web of Science ®Google Scholar
• Buell JF , CherquiD, GellerDAet al. The international position on laparoscopic liver surgery: the Louisville statement, 2008. Ann. Surg.250(5), 825–830 (2009).
   PubMed Web of Science ®Google Scholar
• Castaing D , VibertE, RiccaL, AzoulayD, AdamR, GayetB. Oncologic results of laparoscopic versus open hepatectomy for colorectal liver metastases in two specialized centers. Ann. Surg.250(5), 849–855 (2009).
   PubMed Web of Science ®Google Scholar
• Simillis C , ConstantinidesVA, TekkisPPet al. Laparoscopic versus open hepatic resections for benign and malignant neoplasms – a meta-analysis. Surgery141(2), 203–211 (2007).
   PubMed Web of Science ®Google Scholar
• Pathak S , JonesR, TangJMet al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis.13(9), e252–e265 (2011).
   PubMed Web of Science ®Google Scholar
• Stättner S , JonesRP, YipVSet al. Microwave ablation with or without resection for colorectal liver metastases. Eur. J. Surg. Oncol.39(8), 844–849 (2013).
   PubMed Web of Science ®Google Scholar
• Kingham TP , KarkarAM, D’AngelicaMIet al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J. Am. Coll. Surg.215(3), 379–387 (2012).
   PubMed Web of Science ®Google Scholar
• Mulier S , NiY, JamartJ, RuersT, MarchalG, MichelL. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann. Surg.242(2), 158–171 (2005).
   PubMed Web of Science ®Google Scholar
• McCarley JR , SoulenMC. Percutaneous ablation of hepatic tumors. Semin. Intervent. Radiol.27(3), 255–260 (2010).
   PubMedGoogle Scholar
• Simon CJ , DupuyDE, Mayo-SmithWW. Microwave ablation: principles and applications. Radiographics25(Suppl. 1), S69–S83 (2005).
   PubMed Web of Science ®Google Scholar
• Wong SL , ManguPB, ChotiMAet al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J. Clin. Oncol.28(3), 493–508 (2010).
   PubMed Web of Science ®Google Scholar
• Ruers T , PuntC, Van CoevordenFet al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC intergroup Phase II study (EORTC 40004). Ann. Oncol.23(10), 2619–2626 (2012).
   PubMed Web of Science ®Google Scholar
• Evrard S , RivoireM, ArnaudJPet al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br. J. Surg.99(4), 558–565 (2012).
   PubMed Web of Science ®Google Scholar
• Abulkhir A , LimongelliP, HealeyAJet al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann. Surg.247(1), 49–57 (2008).
   PubMed Web of Science ®Google Scholar
• Covey AM , BrownKT, JarnaginWRet al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann. Surg.247(3), 451–455 (2008).
   PubMed Web of Science ®Google Scholar
• Lam VW , SpiroC, LaurenceJMet al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann. Surg. Oncol.19(4), 1292–1301 (2012).
   PubMed Web of Science ®Google Scholar
• Schnitzbauer AA , LangSA, GoessmannHet al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann. Surg.255(3), 405–414 (2012).
   PubMed Web of Science ®Google Scholar
• Li J , GirottiP, KönigsrainerI, LadurnerR, KönigsrainerA, NadalinS. ALPPS in right trisectionectomy: a safe procedure to avoid postoperative liver failure? J. Gastrointest. Surg.17(5), 956–961 (2013).
   PubMed Web of Science ®Google Scholar
• Azoulay D , AndreaniP, MaggiU. Combined liver resection and reconstruction of the supra-renal vena cava: the Paul Brousse experience. Ann. Surg.244(1), 80–88 (2006).
   PubMed Web of Science ®Google Scholar
• Hemming AW , ReedAI, LanghamMRJr, FujitaS, HowardRJ. Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann. Surg.239(5), 712–719; discussion 719–721 (2004).
   PubMed Web of Science ®Google Scholar
• Kondo S , HiranoS, AmboY, TanakaE, KubotaT, KatohH. Arterioportal shunting as an alternative to microvascular reconstruction after hepatic artery resection. Br. J. Surg.91(2), 248–251 (2004).
   PubMed Web of Science ®Google Scholar
• Lodge JP , AmmoriBJ, PrasadKR, BellamyMC. Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases. Ann. Surg.231(4), 471–479 (2000).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , QuilichiniMA, ParcR, HannounL, DelvaE, HuguetC. Hepatic resection for colorectal liver metastases. Influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann. Surg.205(3), 256–263 (1987).
   PubMed Web of Science ®Google Scholar
• Bhangui P , AdamR. Liver resection of colorectal metastases in elderly patients. Ann. Surg.252(5), 774–787 (2010).
   PubMedGoogle Scholar
• Kulik U , BektasH, KlempnauerJ, LehnerF. Repeat liver resection for colorectal metastases. Br. J. Surg.100(7), 926–932 (2013).
   PubMed Web of Science ®Google Scholar
• Jarnagin WR , GonenM, FongYet al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann. Surg.236(4), 397–406; discussion 406–407 (2002).
   PubMed Web of Science ®Google Scholar
• Dindo D , DemartinesN, ClavienPA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg.240(2), 205–213 (2004).
   PubMed Web of Science ®Google Scholar
• Reddy SK , BarbasAS, TurleyRSet al. A standard definition of major hepatectomy: resection of four or more liver segments. HPB (Oxford)13(7), 494–502 (2011).
   PubMed Web of Science ®Google Scholar
• Cannon RM , MartinRC, CallenderGG, McMastersKM, ScogginsCR. Safety and efficacy of hepatectomy for colorectal metastases in the elderly. J. Surg. Oncol.104(7), 804–808 (2011).
   PubMed Web of Science ®Google Scholar
• Tomlinson JS , JarnaginWR, DeMatteoRPet al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol.25(29), 4575–4580 (2007).
   PubMed Web of Science ®Google Scholar
• Lordan JT , KaranjiaND, QuineyN, FawcettWJ, WorthingtonTR. A 10-year study of outcome following hepatic resection for colorectal liver metastases – the effect of evaluation in a multidisciplinary team setting. Eur. J. Surg. Oncol.35(3), 302–306 (2009).
   PubMed Web of Science ®Google Scholar
• Adamina M , KehletH, TomlinsonGA, SenagoreAJ, DelaneyCP. Enhanced recovery pathways optimize health outcomes and resource utilization: a meta-analysis of randomized controlled trials in colorectal surgery. Surgery149(6), 830–840 (2011).
   PubMed Web of Science ®Google Scholar
• Connor S , CrossA, SakowskaM, LinscottD, WoodsJ. Effects of introducing an enhanced recovery after surgery programme for patients undergoing open hepatic resection. HPB (Oxford)15(4), 294–301 (2013).
   PubMed Web of Science ®Google Scholar
• Schultz NA , LarsenPN, KlarskovBet al. Evaluation of a fast-track programme for patients undergoing liver resection. Br. J. Surg.100(1), 138–143 (2013).
   PubMed Web of Science ®Google Scholar
• Jones C , KelliherL, DickinsonMet al. Randomized clinical trial on enhanced recovery versus standard care following open liver resection. Br. J. Surg.100(8), 1015–1024 (2013).
   PubMed Web of Science ®Google Scholar
• Kopetz S , ChangGJ, OvermanMJet al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol.27(22), 3677–3683 (2009).
   PubMed Web of Science ®Google Scholar
• Konopke R , RothJ, VolkAet al. Colorectal liver metastases: an update on palliative treatment options. J. Gastrointest. Liver Dis.21(1), 83–91 (2012).
   PubMed Web of Science ®Google Scholar
• Giacchetti S , BjarnasonG, GarufiCet al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J. Clin. Oncol.24(22), 3562–3569 (2006).
   PubMed Web of Science ®Google Scholar
• Saltz LB , CoxJV, BlankeCet al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Jones RP , MalikHZ, FenwickSW, PostonGJ. Perioperative chemotherapy for resectable colorectal liver metastases: where now? Eur. J. Surg. Oncol.39(8), 807–811 (2013).
   PubMed Web of Science ®Google Scholar
• Saltz LB , ClarkeS, Díaz-RubioEet al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Hurwitz H , FehrenbacherL, NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneC-H, HitreEet al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med.360(14), 1408–1417 (2009).
   PubMed Web of Science ®Google Scholar
• Vakiani E , JanakiramanM, ShenRet al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol.30(24), 2956–2962 (2012).
   PubMed Web of Science ®Google Scholar
• De Roock W , ClaesB, BernasconiDet al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol.11(8), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, MakhsonAet al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.27(5), 663–671 (2009).
   PubMed Web of Science ®Google Scholar
• Heinemann V , von WeikersthalLF, DeckerTet al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J. Clin. Oncol.31(Suppl.), Abstract LBA3506 (2013).
   PubMedGoogle Scholar
• Jones RP , DunneD, SuttonPet al. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case–control series. HPB (Oxford)15(1), 71–77 (2013).
   PubMed Web of Science ®Google Scholar
• Mitry E , FieldsAL, BleibergHet al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J. Clin. Oncol.26(30), 4906–4911 (2008).
   PubMed Web of Science ®Google Scholar
• Morris EJ , FormanD, ThomasJDet al. Surgical management and outcomes of colorectal cancer liver metastases. Br. J. Surg.97(7), 1110–1118 (2010).
   PubMed Web of Science ®Google Scholar
• Ychou M , HohenbergerW, ThezenasSet al. A randomized Phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol.20(12), 1964–1970 (2009).
   PubMed Web of Science ®Google Scholar
• Adam R , DelvartV, PascalGet al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg.240(4), 644–657; discussion 657–658 (2004).
   PubMed Web of Science ®Google Scholar
• Adam R , BhanguiP, PostonGet al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann. Surg.252(5), 774–787 (2010).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , SorbyeH, GlimeliusBet al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet371(9617), 1007–1016 (2008).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , Van CutsemE, GruenbergerTet al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann. Oncol.20(6), 985–992 (2009).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , SorbyeH, GlimeliusBet al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, Phase 3 trial. Lancet Oncol.14(12), 1208–1215 (2013).
   PubMed Web of Science ®Google Scholar
• Poston G , AdamR, VautheyJN. Downstaging or downsizing: time for a new staging system in advanced colorectal cancer?J. Clin. Oncol.24(18), 2702–2706 (2006).
   PubMed Web of Science ®Google Scholar
• Bismuth H , AdamR, LéviFet al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg.224(4), 509–520; discussion 520–522 (1996).
   PubMed Web of Science ®Google Scholar
• Poston GJ . Staging of advanced colorectal cancer. Surg. Oncol. Clin. North Am.17(3), 503–517 (2008).
   PubMed Web of Science ®Google Scholar
• Adam R , AvisarE, AricheAet al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal [liver] metastases. Ann. Surg. Oncol.8, 347–353 (2001).
   PubMed Web of Science ®Google Scholar
• Folprecht G , GrotheyA, AlbertsS, RaabHR, KöhneCH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol.16(8), 1311–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Nordlinger B , Van CutsemE, RougierPet al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur. J. Cancer43(14), 2037–2045 (2007).
   PubMed Web of Science ®Google Scholar
• Tournigand C , AndréT, AchilleEet al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Colucci G , GebbiaV, PaolettiGet al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol.23(22), 4866–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Falcone A , RicciS, BrunettiIet al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol.25(13), 1670–1676 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneCH, LángIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, HartmannJTet al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol.22(7), 1535–1546 (2011).
   PubMed Web of Science ®Google Scholar
• Folprecht G , GruenbergerT, BechsteinWOet al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised Phase 2 trial. Lancet Oncol.11(1), 38–47 (2010).
   PubMed Web of Science ®Google Scholar
• Garufi C , TorselloA, TumoloSet al. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br. J. Cancer103(10), 1542–1547 (2010).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , RiveraF, BerrySet al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol.20(11), 1842–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Masi G , LoupakisF, SalvatoreLet al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a Phase 2 trial. Lancet Oncol.11(9), 845–852 (2010).
   PubMed Web of Science ®Google Scholar
• Loupakis F , CremoliniC, MasiGet al. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): results of the Phase III randomized TRIBE trial. J. Clin. Oncol.30, (Suppl. 34), Abstract 336 (2012).
   Google Scholar
• Fuchs CS , MarshallJ, MitchellEet al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol.25(30), 4779–4786 (2007).
   PubMed Web of Science ®Google Scholar
• Kneuertz PJ , MaithelSK, StaleyCA, KoobyDA. Chemotherapy-associated liver injury: Impact on surgical management of colorectal cancer liver metastases. Ann. Surg. Oncol.18(1), 181–190 (2011).
   PubMed Web of Science ®Google Scholar
• Welsh FK , TilneyHS, TekkisPP, JohnTG, ReesM. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br. J. Cancer96(7), 1037–1042 (2007).
   PubMed Web of Science ®Google Scholar
• Vauthey JN , PawlikTM, RiberoDet al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol.24(13), 2065–2072 (2006).
   PubMed Web of Science ®Google Scholar
• Auer RC , WhiteRR, KemenyNEet al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer116(6), 1502–1509 (2010).
   PubMed Web of Science ®Google Scholar
• Mocellin S , PilatiP, LiseM, NittiD. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J. Clin. Oncol.25(35), 5649–5654 (2007).
   PubMed Web of Science ®Google Scholar
• Kemeny N , HuangY, CohenAMet al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med.341(27), 2039–2048 (1999).
   PubMed Web of Science ®Google Scholar
• Allen PJ , NissanA, PiconAIet al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J. Am. Coll. Surg.201(1), 57–65 (2005).
   PubMed Web of Science ®Google Scholar
• Martin RC , JoshiJ, RobbinsK, TomaltyD, O’HaraR, TatumC. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-Institutional registry. J. Oncol., 539795 (2009).
   PubMedGoogle Scholar
• Richardson AJ , LaurenceJM, LamVW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J. Vasc. Interv. Radiol.24(8), 1209–1217 (2013).
   PubMed Web of Science ®Google Scholar
• Fiorentini G , AlibertiC, TilliMet al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a Phase III study. Anticancer Res.32(4), 1387–1395 (2012).
   PubMed Web of Science ®Google Scholar
• Martin RC , ScogginsCR, TomaltyDet al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and Phase I trial. J. Gastrointest. Surg.16(8), 1531–1538 (2012).
   PubMed Web of Science ®Google Scholar
• Van Hazel G , BlackwellA, AndersonJet al. Randomised Phase 2 trial of sir-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J. Surg. Oncol.88(2), 78–85 (2004).
   PubMed Web of Science ®Google Scholar
• Sharma RA , WasanHS, LoveSB, DuttonS, StokesJC, SmithJL. FOXFIRE: a Phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin. Oncol.20(3), 261–263 (2008).
   PubMed Web of Science ®Google Scholar
• Segelman J , SingnomklaoT, HellborgH, MartlingA. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis.11(7), 768–774 (2009).
   PubMed Web of Science ®Google Scholar
• Jones RP , VautheyJN, AdamRet al. Effect of specialist decision-making on treatment strategies for colorectal liver metastases. Br. J. Surg.99(9), 1263–1269 (2012).
   PubMed Web of Science ®Google Scholar